BCAX Healthcare

Bicara Therapeutics Inc.

$8.96+12.99%

Price as of close on Nov 3, 2026 · Financials updated Oct 30, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 592.9M USD
Enterprise value: 96.8M USD
Full-time employees: 103

Overall health

Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Not enough data: growth

Would rank #825 of 1,157 fully scored healthcare companies (bottom 29%)

Partial overall score — 3/4 categories available.

See how it ranks against its peers

Worth knowing

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Bicara Therapeutics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss in the 12 months to June 2026.
Bicara Therapeutics reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.
Little borrowing. Debt is 0.00× equity vs a peer median of 0.2×.Debt is 0.00× equity vs peers 0.2×.
Bicara Therapeutics has among the least debt in its peer group relative to shareholders' equity.

StockQuotient Score

40/ 100

Oct 5 40 → Nov 4 40

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-17.4%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-208.5%

Yahoo Finance fallback · SEC enterprise value unavailable (debt or EBITDA not reported in standard form) · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-12.7%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield44.0%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

Insufficient data

Insufficient data: 1 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Profitability

Does it earn well?

17/100

Weak

2/3 inputs reported · Partial data

Since last quarter: No major change

Why

Weaker than most peers on:

▼ ROA
▼ ROIC

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating marginUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0706 · MAD: 0.1217

Return on assets-36.2%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -7.05Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-42.9%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -4.74Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin0.0%

Yahoo Finance fallback · SEC figure unavailable or out of date · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-39.5%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

2/3 inputs reported · Partial data

Since last quarter: No major change

Why

Stronger than most peers on:

▲ Debt / equity
▲ Current ratio

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

BetaUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.6250 · MAD: 0.3380

Current ratio11.59×

SEC filings · latest balance sheetReported value33% base weight · Z-score 6.50Sector median: 2.5860 · MAD: 1.3850

Debt / equity<0.01×

Yahoo Finance fallback · no standard SEC debt tagOutlier capped at sector 5th/95th percentile33% base weight · Z-score 1.07Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Bicara Therapeutics

Is Bicara Therapeutics getting weaker?: Its latest SEC filing (Aug 11, 2026) showed no major changes. Its overall score is unchanged at 40/100 since Oct 28, 2026.
How is Bicara Therapeutics valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -17.4% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -17.4% vs peers 1.5% (weaker than 100% of peers).
Is Bicara Therapeutics growing?: Insufficient data: 1 of 3 inputs reported (at least 2 needed).
How profitable is Bicara Therapeutics?: Less profitable than most of its peers. Profitability scores 17/100 against 1,393 healthcare peers. Return on assets -36.2% vs a peer median of 1.7% (weaker than 89% of peers).Return on assets -36.2% vs peers 1.7% (weaker than 89% of peers).
How risky is Bicara Therapeutics?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity <0.01× vs a peer median of 0.22× (stronger than 95% of peers).Debt / equity <0.01× vs peers 0.22× (stronger than 95% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 11, 2026 · compared with the quarter ended Mar 31, 2026

No major changes

Worth watching: Bicara Therapeutics is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.

	Previous quarter	Latest quarter	Change
Net income (12 months)	−157.3M USD	−185.4M USD	+17.8%
Free cash flow (12 months)	−116.6M USD	−135.2M USD	+16.0%
Cash	323.5M USD	96.6M USD	−70.1%
Shares outstanding	65.7M	66.2M	+0.7%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2023	FY 2024	FY 2025	Change
Return on assets (ROA)	-22.2%	-13.3%	-32.0%	▼ 19 pts
Return on equity (ROE)	—	-13.8%	-34.4%	▼ 21 pts
Current ratio	15.32×	27.93×	14.58×	▼ 48%

BCAX price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Not enough data: growth

Would rank #825 of 1,157 fully scored healthcare companies (bottom 29%)

Partial overall score — 3/4 categories available.

See how it ranks against its peers

Worth knowing

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Bicara Therapeutics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss in the 12 months to June 2026.

Bicara Therapeutics reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Little borrowing. Debt is 0.00× equity vs a peer median of 0.2×.Debt is 0.00× equity vs peers 0.2×.

Bicara Therapeutics has among the least debt in its peer group relative to shareholders' equity.

Questions investors ask about Bicara Therapeutics

Is Bicara Therapeutics getting weaker?

Its latest SEC filing (Aug 11, 2026) showed no major changes. Its overall score is unchanged at 40/100 since Oct 28, 2026.

How is Bicara Therapeutics valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -17.4% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -17.4% vs peers 1.5% (weaker than 100% of peers).

Is Bicara Therapeutics growing?

Insufficient data: 1 of 3 inputs reported (at least 2 needed).

How profitable is Bicara Therapeutics?

Less profitable than most of its peers. Profitability scores 17/100 against 1,393 healthcare peers. Return on assets -36.2% vs a peer median of 1.7% (weaker than 89% of peers).Return on assets -36.2% vs peers 1.7% (weaker than 89% of peers).

How risky is Bicara Therapeutics?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity <0.01× vs a peer median of 0.22× (stronger than 95% of peers).Debt / equity <0.01× vs peers 0.22× (stronger than 95% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Net income (12 months)

−157.3M USD

−185.4M USD

+17.8%

Free cash flow (12 months)

−116.6M USD

−135.2M USD

+16.0%

Cash

323.5M USD

96.6M USD

−70.1%

Shares outstanding

65.7M

66.2M

+0.7%

Key ratios

FY 2023

FY 2024

FY 2025

Change

Return on assets (ROA)

-22.2%

-13.3%

-32.0%

▼ 19 pts

Return on equity (ROE)

—

-13.8%

-34.4%

▼ 21 pts

Current ratio

15.32×

27.93×

14.58×

▼ 48%